" class="no-js "lang="en-US"> Immunovia - Medtech Alert
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
Immunovia | Pharmtech Focus

Immunovia

About Immunovia

Immunovia

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see:

Related Story

Appointments

 Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs | PTF

Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs

January 17 2023

Immunovia, the diagnostics company that has launched the world’s first blood test dedicated to the […]

Diseases

 The PanDIA-1 Study

The PanDIA-1 Study, for Early Detection of Pancreatic Cancer in Newly Onset Type 2 Diabetics, Moves Into Next Phase

June 30 2022

Immunovia today announced the PanDIA-1 study for the early detection of pancreatic cancer in newly […]

Appointments

 Immunovia Appoints Jeff Borcherding

Immunovia Appoints Jeff Borcherding, Previously Chief Marketing Officer at Myriad Genetics, to Lead Immunovia's US Business

March 28 2022

Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Jeff Borcherding as CEO of its US subsidiary Immunovia, Inc. He […]